Key facts
- Epikast’s last known valuation is $37.2M (Jan 2026).
- It has raised $12.2M across 2 recorded rounds; the latest was Seed Round ($700K) in Jan 2026.
- Notable investors include EcoR1 Capital, Jesús Mantas, Kos Biotechnology Partners, Synetro Group.
- Epikast has filed 1 Form D with the SEC, most recently Feb 2023 ($5.0M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Epikast
Funding rounds
2 roundsAbout Epikast
Developer of a healthcare engagement platform designed to create personalized experiences for patients, physicians, and other healthcare professionals and caregivers. The company's platform offers services that focus on minimizing the bureaucratic and administrative burden for patients and physician offices and redefining how biopharmaceutical companies engage with stakeholders, enabling physicians to improve overall patient engagement and outcomes.
- Sector
- Information Technology
- HQ
- New York, NY, United States
- Founded
- 2022
- Employees
- 60
- Website
- epikast.com/
- Ownership
- Privately Held (backing)
Epikast doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epikast shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epikast in its N-PORT filings yet. We sweep new filings monthly.